Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma

Lee, Ho; Kim, Kyung Ryoul; Noh, Sang Jae; Park, Ho Sung; Kwon, Keun Sang; Park, Byung‐Hyun; Jung, Sung Hoo; Youn, Hyun Jo; Lee, Byoung Kil; Chung, Myoung Ja; Koh, Dai Ha; Moon, Woo Sung; Jang, Kyu Yun

doi:10.1016/j.humpath.2010.05.023

Cited by 141 publications

(173 citation statements)

References 40 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…The present study identified an association of SIRT1 overexpression with shorter OS time and poor prognostic indicators in SCC, which was consistent with the results of previous studies (4,36,45). By contrast, certain reports have found a significant association between SIRT1 overexpression and more favorable prognosis in serous carcinoma of the ovary (46) and colorectal cancer (47,48).…”

Section: A B C Dsupporting

confidence: 93%

“…malignancies (6,42), and changes in SIRT1-mediated signaling allows mammalian cells to survive under oxidative stress and DNA damage, which are closely associated with tumorigenesis (43,44), cancer progression and poor prognosis in cancer patients (3,4,36). The present study identified an association of SIRT1 overexpression with shorter OS time and poor prognostic indicators in SCC, which was consistent with the results of previous studies (4,36,45).…”

Section: A B C Dsupporting

confidence: 92%

See 1 more Smart Citation

Association of SIRT1 and HMGA1 expression in non-small cell lung cancer

Lin¹,

Peng²

2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The roles of Silent mating type information regulation 2 homolog 1 (SIRT1) and High mobility group A1 (HMGA1) in human diseases have been extensively studied separately; however, to the best of our knowledge, the current study is the first to report on their interrelationship in lung cancer. The association of SIRT1 and HMGA1 in non-small cell lung cancer (NSCLC) was investigated by evaluating their expression and prognostic significance in 260 patients with NSCLC using immunohistochemistry. SIRT1 and HMGA1 expression were found to be significantly correlated with each other (P<0.001), and both were significantly associated with clinicopathological parameters, including histological type and degree of differentiation. In squamous cell carcinoma (SCC), SIRT1 + specimens were significantly associated with shorter overall survival (OS) time (P=0.019). However, in patients with adenocarcinoma (AD), no association was identified between SIRT1 and OS. In addition, HMGA1 + specimens were significantly associated with poor differentiation (P=0.028), and were more frequent in SCC than AD (P=0.015). However, HMGA1 was not associated with OS on univariate Cox regression analysis or Kaplan-Meier analysis (both P>0.05). SIRT1/HMGA1 coexpression was significantly associated with male gender (P=0.016), and moderately and poorly differentiated histological grade (P=0.025). The findings indicate that SIRT1 and HMGA1 may have significant effects during tumor progression in NSCLC, particularly in patients with SCC, and are potentially useful as prognostic indicators for patients with NSCLC.

show abstract

Section: A B C Dsupporting

confidence: 93%

Section: A B C Dsupporting

confidence: 92%

Association of SIRT1 and HMGA1 expression in non-small cell lung cancer

Lin¹,

Peng²

2015

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…DBC1 potentiates ERα transcriptional activity by inhibiting the association of sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide-dependent deacetylase, with both ERα and the SIRT1-mediated deacetylation of ERα. DBC1 and SIRT1 expression correlates with more distant metastatic relapses and a shorter period of relapse-free survival in breast cancer patients [181]. Ciz1 is a novel coactivator of ERα involved in DNA replication and cell cycle regulation.…”

Section: Estrogen Receptor Coregulators In Breast Cancer Coactivatorsmentioning

confidence: 99%

RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy

Zhou

Qiao

Shetty

et al. 2013

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Estrogen and estrogen receptors (ERs) are critical regulators of breast epithelial cell proliferation, differentiation, and apoptosis. Compromised signaling vis-à-vis the estrogen receptor is believed © Springer Basel 2013 yow4@pitt.edu. ), which predicts for response to endocrine-based therapy; however, innate or acquired resistance to endocrinebased drugs remains a serious challenge. The complexity of regulation for estrogen signaling coupled with the crosstalk of other oncogenic signaling pathways is a reason for endocrine therapy resistance. Alternative strategies that target novel molecular mechanisms are necessary to overcome this current and urgent gap in therapy. A thorough analysis of estrogen-signaling regulation is critical. In this review article, we will summarize current insights into the regulation of estrogen signaling as related to breast carcinogenesis and breast cancer therapy. NIH Public Access

show abstract

“…Correlations of SIRT1 expression with clinico-pathological features in different cancer types and with patients prognosis also suggest different contribution of SIRT1 to cancer outcome, including responses to therapy. SIRT1 overexpression positively correlates with poor prognosis in B cell lymphoma [15], gastric cancer [16] and breast cancer [17], while it is related to favorable outcome in ovarian epithelial cancer [18]. Currently, the molecular background that determines participation of SIRT1 to tumor development and responses to the therapy is yet to be clarified.…”

Section: Introductionmentioning

confidence: 99%

High SIRT1 expression and low DBC1 expression are associated with poor prognosis in colorectal cancer

Kikuchi¹,

Noguchi²,

Takahashi³

et al. 2013

J Cancer Ther Res

View full text Add to dashboard Cite

Background: SIRT1 deacetylates various cellular proteins in addition to histones and functions as an either tumor-promoter or tumor-suppressor. The participation of SIRT1 in colorectal cancer onset and progression remains controversial. SIRT1 activity is regulated among the others by deleted in breast cancer 1 (DBC1). We asked if the expression of the SIRT1-inhibitor DBC1 affects contribution of SIRT1 to colorectal cancer.

show abstract

Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma

Cited by 141 publications

References 40 publications

Association of SIRT1 and HMGA1 expression in non-small cell lung cancer

Association of SIRT1 and HMGA1 expression in non-small cell lung cancer

RETRACTED ARTICLE: Regulation of estrogen receptor signaling in breast carcinogenesis and breast cancer therapy

High SIRT1 expression and low DBC1 expression are associated with poor prognosis in colorectal cancer

Contact Info

Product

Resources

About